MetaVia rises on regulatory nod to begin early-stage obesity trial

Shares of drug developer MetaVia MTVA.O rise 5.9% to $1.61 premarket

Co says a U.S. Institutional Review Board has cleared its early-stage trial of its experimental dual-action obesity drug, DA‑1726

The approval from the Institutional Review Board at Clinical Pharmacology of Miami allows co to start enrolling participants in the next portion of the early‑stage trial, which is designed to assess higher doses of the drug through two different titration regimens

MetaVia says the Part 3 of early-stage trial will enroll 40 otherwise healthy adults with obesity

The study will measure safety, tolerability, pharmacokinetics and pharmacodynamics of DA‑1726, an oxyntomodulin analog that targets GLP‑1 and glucagon receptor - MTVA

Up to last close, stock has been down ~82% YTD